IMMUNOLOGICAL ASSAY FOR SPONGIFORM ENCEPHALOPATHIES

Abstract: The invention relates to a method of detecting Transmissable Spongiform Encephalopathies (TSE) in animals, particularly in animal carcasses, using an anti-PrP<SC> antibody in an immunological assay. Also disclosed is a diagnostic kit for detecting TSE comprising the same antibody.

Description: Immunoloαical assay for Spongiform Encephalopathies The present invention relates to method of detecting Transmissable Spongiform Encephalopathies and to an im unological assay or test for Transmissable Spongiform Encephalopathies (TSE). Background to the invention Spongiform Encephalopathies are a group of degenerative neurological diseases. There are a number of examples of Spongiform Encephalopathies including BSE (Bovine Spongiform Encephalopathy) , Scrapie, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Straussler- Scheinker Syndrome, Kuru, Transmissable Mink Encephalopathy, Chronic wasting Disease of Mule Deer, Feline Spongiform Encephalopathies and other Spongiform Encephalopathies found in animals such as elk, nyala, greater kudu, gemsbok and tigers. It has also been reported that BSE can be transmitted under laboratory conditions to mice and pigs. This crossing of species barriers by the infective agent has led to increased concern that transfer to humans could occur. Bovine Spongiform Encephalopathy (BSE) is a degenerative brain disorder of cattle which is popularly known as "mad cow disease". It has a slow incubation period, up to four or five years with symptoms of progressive degeneration of the mental state in cows include loss of coordination and staggering gait, lack of interest in their surroundings, disinterest in feed and water, or unpredictable behaviour, including aggressiveness. Affected cattle show symptoms when they are three to ten years old. First identified in Great Britain in November 1986, over 100,000 cases have since been recorded there. Post morte s of affected cattle reveal a characteristic pattern of vacuolation in the brain tissue due to destruction of neural cells and the deposition of unusual protein fibres, that give the brain a spongy (spongiform) texture. Similar spongiform diseases have been recognized in humans (for example, Creutzfeldt-Jakob disease or CJD) for over a century and in sheep (scrapie) for over 200 years. The agent thought to be responsible for BSE and its counterparts is an infective protein known as a p ion. The prion is an infective particle comprising protein only and no nucleic acid, the presence of nucleic acid being required in the case of a conventional virus. In Scrapie in particular one protein known as prion protein or PrP . has been found to co-purify with infectivity and can produce a Scrapie-like condition in brain cell cultures from sc other animals, such as hamsters under laboratory conditions. PrP is the only known component of the characteristic protein fibres deposited in the brain tissue of Scrapie-infected sheep. This protein, the PrP appears to undergo a structural modification, whereas the term PrP is used in resDect of the normal cellular counterpart of PrP sc . The natural function of PrP is not known, but it appears likely that i has an essential structure or functional role in the organism. Recycled animal tissue, wnich had been routinely ted to British dairy cows as a protein supplement has been identified as the source of the infection. It is believed that BSE was originally spread from sheep's brains infected with scrapie and that its spread was accidentally accelerated by the ingestion of brain tissue taken from cows that had become infected with BSE. Therefore, the British Government introduced compulsory destruction of suspect animals and their carcasses beginning in 1988. The feeding of animal tissue to cows was banned in Britain in July 1988. Since the initial report of the disease, consumers have feared that it might be transferable to humans through milk or beef products, particularly since Kuru, a related disease is known to be spread by ritualistic cannibalism among New Guinea tribesmen. In late 1990, consumer concern over the transmission of BSE to humans triggered a collapse in the beef market. A similar scare struck Germany in mid-1994. In 1996 ten cases of a newly described type of fatal CJD (Variant CJD) were identified. The victims had distinct brain tissue symptoms, were all under the age of 42, and had no hereditary record of the disease. It has been suggested that the victims may have contracted the disease through contact with BSE-infected cattle before the eradication of suspected animals had taken effect. The identification of Variant CJD led to a dramatic drop in beef consumption in Britain, ana the banning of British and in some instances Irish beef imports in various countries worldwide. Therefore, for both veterinary and economic reasons, there is an urgent need to provide a method for diagnosis and a diagnostic kit to detect infection with BSE, Scrapie and other related Spongiform Encephalopathies. in livestock, animal carcasses and meat generally. Ob.iect of the invention It is therefore an object of the present invention to provide a method of testing cattle, particularly animal carcasses, for the infective agent responsible for BSE. It is also an object that protection methoα be rapid, with the result being available in a matter of hours, that it should be cheap, eliable and user-friendly. Such a detection method would have the advantage that it would prevent the entry of infected meat into the human food chain, thus eliminating the possibility of humans contracting Variant CJD or other related diseases which may be transmitted by eating infected meat. It has the further advantage that it would restore consumer confidence in meat and meat products, which would be advantageous for both the fanning community and the meat industry in general. At present there is no test available which can identify infected meat carcasses or livestock carcasses, and there is no product available which can allay public fears regarding meat consumption. The current invention provides an im unological assay for the putative agent PrP the rogue prion protein believed to be responsible for Spongiform Encephalopathies. Summary of the invention According to the present invention there is provided a method for detecting the putative agent for TSE in animals comprising taking a body tissue sample from an animal, reacting the sample in a immunological assay with a labelled antibody which is capable of rreeaaccttiinngg wwiitthh PPrr 55 and determining the amount, of label lea antibody bound to the sample. Suitably , the antibody used in the assay is raised against a syntheti c peptide sequence having the general formul a : X- ( R 1 -Lys-Hi s- 2 ) -Al a-Giy-Al a-Al a-Al a-R 3 -Gly-Al a-VaI -Val -Gl y-G ly-Leu- l v-Gl y-Tyr-Met-Leu-Gl y-Ser-Al a-Met-Ser-(Arg-Pro-R 4 -R c ) -V wherein R 1 is an amino acid residue selected from Met. Leu and Phe; R„ s either Met or Val ; R- j is Ala or is absent; R„ and R,- are independently an ammo acid residue selected • * ZS from i.eu. He and Met: one or more residues within brackets maybe present or absent with the provisio that : f they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently De absent or independently be one or more additional mmo acid residues. Particularly preferred are prion specific antibodies raised against one or more of the following sequences: VKSHIGSWILVLFVVAMWSDVGLCKKRPKPGGGWNTGGSRYPGO-44 GSPGGNRYPP0GGGGWG0PHGGGWG0PHGGGWG0PHGGG0GQP-87 GGGGWG0GGSHSQWNKPSKPPKTNMKHVAGAAAGAVVGGLGGY-131 MLGSAMSSPLIHFGNDYEDRYTRENMYRYPNQVYYRPVDRYSNQNN-177 More particularly preferred are antibodies raised against the underlined sequences shown above. The antibody used in the assay is preferably a C5 antibody to SC PrP which is available from Proteus, England, called herein the differentiation reagent. Other anti-PrP sc antibodies are also suitable for use in the invention. Suitable antibodies are those directed against the synthetic peptides disclosed in WO 93/11155. The immunological assay may be a competitive assay in which a solid support, suitably a microtitre plate, is pre-coated with a carrier protein-peptide conjugate, the animal tissue sample and an anti-peptide antibody re added to the solid support, allowed to react a d the support washed, a labelled antι-( anti-peptide antibody) antibody is added, allowed to react, washed, a signal reagent added and the signal read. The label may be horseradish peroxidase. The primary antibody used in the assay is preferably a rabbit anti-P P antibody and the secondary antibody is preferably selected from a goat, sheep, donkey or other anti-rabbit antibody. In a particular embodiment an ELISA assay can be used to identify the peeppttiiddee ffrraaggmmeenntt for PrP L , but other suitable immunological assays could be used. 10 In a preferred embodiment an enhanced chemi luminescence assay is used to aid detection of the Pr 5C agent. The animals may suitably be cattle, sheep and Digs and the tissue sample may suitably be taken from a carcass o sucn animals. lϋ The steps involved are: 1. Clean up of nervous tissue to allow detection of putative agent ffoorr PPrrPP ((tthhee rroogguuee pprriioonn ppnrotein believed responsible for 0 Spongiform Encephalopathies) ; 2. Assay priming step involving addition of specific agents (antibodies); 25 3. ELISA using wells pre-coated with peptide fragment for PrP sc ; 4. Enhanced chemi luminescence assay for detection of PrP sc agent; and 30 5. Determination of results. In particular the assay involves assay for the PrP sc protein which is the infective prion protein found in BSE. The assay is capable of distinguishing between PrP sc and PrP sc which is the 35 normal BSE prion protein. The PrP sc protein is a series of peptides sc in a triple helix whereas m PrP one third of the molecule is in the form of a flat beta-sheet. It 's particularly important that the assay can discriminate between natural PrP and PrP^ , since PrP c is found in normal c sc subjects while both PrP and PrP are found in diseased subjects. In a particularly preferred embodiment, a sample of CNS tissue. suitably a cross-section of spinal cord, is removed from an animal carcass, homogenised, f ltered and plated onto a microtitre tray. The sample s then reacted in an immunological assay with an antibody as described above. The invention also provides a test kit for the detection of TSE in animals comprising an anti-peptide antibody as defined above. The method allows the rapid detection of a TSE agent in a carcass, Λ/ith results being available in a matter of hours, usually about one and a half to two hours. Thus the carcass can be removed om the abattoir before passing into the human food chain. Detailed description of the invention The invention will now be described in greater detail with reference to the Examples. The requirements for the Enfer TSE immunoassay are as follows: a) A sample of CNS tissue b) A series of preparative sample treatments c) A prion specific antibody d) Sensitive method of detection a) A sample of CNS tissue is removed from a beef carcass at the point of slaughter using a specialised sampling clavical (available from Medisteel, Dublin, Ireland). This tissue sample must be such that a cross-section of spinal cord can be removed from the sample for confirmatory analysis if necessary. The sample is placed in a universal container and is identified with a traceable identification number i.e. an EU 4 digit carcass number, an Irish Department of Agriculture ear-tag number or a traceable factory kill number. The sample i transported to the laboratory for testing. b) On reaching the laboratory the sample is identified using barcodes. The barcode assigned to each sample incorporates information on the factory of origin of the sample, the date the animal is killed and a traceable identification sample number. An amount of each 5 sample, ranging weight from 0.3g to l.lg, is removed and placed into a stomacher bag for homogemsation. This bag containing a section of the original sample wil oe assigned an identical barcode to the original sample. This allows full traceability throughout the system. Λ fixed volume o Homoαemsmg Buffer is added to the stomacher Dag and 10 the sample homoqemsed. T η e sample is then dispensed in duplicate onto a prepared 96 well microtitre plate. A fixed volume of Differential Buffer is applied to the microtitre plate and incubated. A fixed volume of Priming Buffer is then added to the samples on the plate and incubated. This step completes the sa pie preparation procedure. i 5 c) The samples are now ready for immunoassay. This requires a prion specific antibody. This antibody is raised in rabbits to a synthetic prion peptide. A fixed volume of this specific antibody is added to the microtitre plate, incubated and washed. A fixed volume of 20 secondary antibody is added to the plate, incubated and wasned. Detection of results is now possible. d) Detection of results is by means of Enhanced Chemi luminescence. A fixed volume of a chemi luminescence reagent is added to the microtitre 25 plate and incubated. The light signal is read using a Labsyste s Chemi luminometer, the results assigned to the corresponding barcode and a results report printed. Example 1 30 REAGENTS REAGENTS FOR HOMOGENlSATICN OF SAMPLES 35 Enfer Homogenisation Buffer (HB) Reverse Osmosis Water Differentiation Reagent Positive Control Negative Control Enfer Immunoassay Priming Buffer (ΪPB) REAGENTS FOR THE IMMUNOASSAY PROCEDURE 1.5 M Phosphate Buffered Saline (PBS) 150m Phosphate Buffered Saline (PBS)/Tween 20 (0.05%) Sodium Chloride Solution (NaCl) Rabbit Anti-PrP peptide in 150 mM PBS/Tween 20 (0.05%) diluted as instructed by the supplier Normal Goat Serum Donkey Anti-Rabbit IgG-Horse Radish Peroxidase conjugate in 150mM P8S/Tween 20 (0.05^) diluted as instructed by the supplier A erlite Reagent Johnson & Johnson Clinical diagnostics EQUIPMENT Bar-code reader and computer database interface Bar-code label printer Rotating (bottle) mixer 96 well microtitration plate chemi luminescence reader 96 well microtitration plate shaking incubator (2) 96 well microtitration plate washer (2) Micro-computer Laser D rinter Micro-computer 'custom' software - data processing and reporting Deep Freeze Storage -20 C Refrigerated Storage 4°C Reverse Osmosis Water System Automated 8 channel pipettes Automated microtitre plate strip dispenser Vortex Mixer Disposable Pasteur pipettes Stomacher ho ogeniser and bags (variable quantity) Blades Secure sample boxes and transport trailers Class II Safety Cabinet system Autoc ave SAMPLES AND SAMPLING PROCEDURE SC The sample shall be such as to enable the detection of PrP protein in spinal chord. The size of the sample will be sufficient to permit the primary analysis and if necessary, a repeat or confirmatory analysis to be carried out. Samples will be taken in a manner which will ensure tnat a fixed amount cf tissue will be taken for each sample. Samples will be taken in a manner which will permit identi ication of the sample m the laboratory. The method of packaging,, preservation and transport to the laboratory Λ- '1 maintain the mtegπ ' ty of the sample such that the results of the an ivS'S '3 not prejudiced. Samples for analysis will be transported to the laboratory, in insulated and sealed containers. PROCEDURE H0M0GENISATI0N AND PREPARATION OF TISSUE 7.5 ml Ho ogeπisation Buffer (HB) is added to each sample. The sample is sealed and placed in the ho ogeniser, homogenise for 3 minutes. Remove the sample from the homogeniser and after accumulation of 40 samples, place the samples onto a designated rack. Apply 0.02ml differentiation reagent to each well of the pre-coated microtitre plate except wells A1,A2. Transfer, in order, the identification bar-code of each sample to the microcomputer with a bar-code scanner. Apply 0.18ml of sample to each well except Al, A2, A3, A4 (controls). Cover the plate with a microtitre plate sealer. Incubate the microtitre plate for 1 hour at 37°C, shaking. Wash the microtitre plate wells 8x with 0.4ml NaCl solution. Dispense 0.25ml of the I munoassay Priming Buffer to each well. Incubate the microtitre plate for 15 minutes at 37°C, shaking. ' wash the microtitre plate wells x with 0.4m! PBS/Tween 20 (0.05<ι solution. CHEMILUMINESCENT IMMUNOASSAY Dispense 0.2ml primary antibody into each well of the microtitration plate. Incubate the microtitration olate for 40 minutes, with shakinq, at 37"C. Wash the microtitration plate wells 4* with 0.4ml of PBS/Tween 20 (0.05 ) solution. Dispense 0.2ml secondary antibody into each well of the microtitration plate. Incubate the microtitration plate for 30 minutes, with shaking, at 37°C. Wash the microtitration oiate wells 4χ it 0.4ml of PBS/Tween {0.05 c ?) solution. Tm Dispense 0.15ml Amer ' nte a ent into each well of the microtitration plate. Incubate the microtitration plate for 3 minutes, with shaking, at 37°C. Read the luminescence in the reader. Data reduction and interpretation. CALCULATION OF RESULTS N/Λ ANTIBODIES, HOMOGENISATI0N BUFFER, IMMUNOASSAY PRIMING BUFFER. QUALITY CONTROLS ANTIBODIES * rabbit Anti-PrP peptide, stored frozen and diluted to working strength as instructed by the supplier. * donkey Anti-Rabbit IgG-Horse Radish Peroxidase (HRP) conjugate, stored at 4 C, to be diluted as instructed by the supplier. * normal goat serum, stored at 4°C, to be diluted as appropriate. QUALITY CONTROLS Supplied by Veterinary Research Laboratories, Abbotstown, Dublin, 5 SOURCE OF ALL REAGENTS Enfer Scientific Ltd, , Co. Tipoerary, Ireland. 10 FLOW DIAGRAM CNS Tissue Sample 0 Homogenisation and Preparation 25 30 immunoassav 35 Report. Result Example 2 1. Homogenisation: 1.1 lg of CNS tissue is removed from the sample and placed in a stomacher bag. • .2 15ml of Homogenising Buffer is added to the section. 1-3 τ his mixture is homogenised for 3 minutes using a stomacher homogeniser. 1.4 The resultant homogenate is filtered through a 1 micron filter. 2. Plating; 2.1 96-well microtite plate is prepared by dispensing 200 ul of Adhering Agent into each well and incubating overnight at 37°C. 2.2 Wash the plate 4XPBST (5 x Phosphate Buffered Saline tablets, supplied by Sigma, U.K., to 1 litre reverse osmosis H ? 0/1% Tween 20) (150mM) before use. 2.3 200ul of blank control (such as water, saline solution or buffer) is dispensed in duplicate onto the plate, positions Al ,2. 2.4 200ul of negative control (known negative BSE homogenate) is dispensed - 4 replicates - onto the plate, positions B1.2 C1.2. The known negative BSE homogenate is supplied by the Veterinary Research Laboratory, Abbotstown, Castleknock, Dublin, Ireland. 2.5 200ul of positive control (known positive BSE homogenate, available from the Veterinary Research Laboratory, Abbotstown, Castleknock, Dublin, Ireland) is dispensed - 4 replicates - onto the plate, positions Dl,2 El, 2. 2.6 200ul of each filtered homogenate is dispensed in duplicate onto the elate, re ainino positions. 2.7 50ul of Differential Buffer is dispensed onto the plate bringing the well volume to 250υl. 2.8 The plate is covered with a microtitre plate sealer and incubateα at 20 C for 30 minutes. 2.9 The plate is centrifuge for 30 minutes at 2000rpm. 2.10 The plate is then washed times with 150mM PBST. 2.11 50'ji of Pπππnα Bu fe r are added to each eH of the mic oti e plate and the oiate cubated for i hour at 37°C. 12 The plate is washed tunes with 150mM PBST 3. Im unoassav: 3.1 250ul of primary prion specific antibody, a rabbit anti-Prion peptide antibody at a dilution of 1:2000, is dispensed onto the plate. 3.2 The plate is incubated at room temperature for 40 minutes. 3.3 The plate is washed 4 times with 150mM PBST. 3.4 250ul of secondary antibody, a donkey-anti -rabbit HRP at a dilution of 1:2000 is dispensed onto the plate and the plate incubated at 37 C for 30 minutes. 3.5 The plate is washed 4 times with 150mM PBST. 4. Detection: 4.1 250ul of Enhanced Chemi luminescent reagent (amerlite reagent, supplied by Johnson & Johnson Clinical Diagnostics, U.K.) is added to the plate. 4.2 e plate is mcubated nt room temperature for 10 minutes. 4.3 The light signal is read using a Labsystems Chemi luminometer (supplied by Medical Supply Co., Dublin, Ireland), which is a scanning wavelength reader. The device reads the luminescence from each well of the plate by scanning the entire IR-visible- UV spectra and extrapolating results. 4.4 The light signals from the plate are transferred to a customised software package (available from G.K.S. Software, Dublin. Ireland), .5 Each light signal is assigned to a corresponding barcoσe and a repor printed. 4.6 Results are quoted in chemi luminescent light unit L.U. SOURCE OF REAGENTS 1. Plate Adhering Agent, Homogenising Buffer, Priming Buffer and Differential Buffer are supplied by Enter Products Ltd. 2. Prion Specific Antibodies - anti-PrP - are supplied by Enfer Products and are rabbit antibodies raised to the following synthetic prion peptides. PRION SEQUENCE N-TERMINAL MVKSHIGSWILVLFVVAMWSDVGLCKKRPKPGGGWNTGGSRYPGO-44 GSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGQGQP-87 GGGGWGOGGSHSQWNKPSKPPKTNMKHVAGAAAGAVVGGLGGY-131 MLGSAMSSPLIHFGNDYEDRYTRENMYRYPNQVYYRPVDRYSNQNN-177 All the sequences used herein are given using standard I.U.P.A.C. three letter code abbreviations for amino acid residues to find as fol lows: A - Alanine, C - Cysteine, D - Aspartic acid, E - Glutamic acid, F - Phenylalanine, G - Glycine, H - Histidine, I - Isoleucine, K - Lysine, L - Leucine, M - Methionine, N - Asparagine, P - Proϋne, Q - Glutamine, R - Arginine, S - Serine, τ - Threonine, V - valine, W - tryptophan and Y - tyros ine. Both underlined sequences, (a 34 amino-acid peptide and a 40 amino acid peptide) are used to raise rabbit anti-PrP antibodies. The peptides are conjugated to activated ovalbumin and injected intra-muscularly in Freund's Complete Adjuvant. Booster injections are sub-cutaneous and Freund's Incomplete Adjuvant is used. The rabbits are bled at 30 days. 3. Chemi luminescent reagent is supplied by Johnson and Johnson. Clinical Diagnostics, U.K. and results are read using a Labsystems Chemi luminometer. Example 3 VALIDATION DATA 1. INTER-ASSAY VARIATION Data generated on a positive control and a negative control, in a total of 10 assays are provided in Table 1. These controls have been deemed positive and negative by two unrelated methods - histology (HIS) and immunohistochemistry (ICC), methods which will ultimately be used to confirm results reported using the Enfer test. The inter-assay variations based on these two samples are ]___ for the positive control and 93% for the negative control. These data indicate that the assay has acceptable reproducibil ity. Another control was also included in this study. This was a peptide control which allows study of the variation between assays due to antibody differences from day to day. These data are included in Table 1. Again the inter-assay variation at 14% is satisfactory. 2. INTRA-ASSAY VARIATION The intra-assay variation was determined using the same type controls as those used for the inter-assay study (positive, negative and peptide) and placing 23 replicates of each control on a single plate. Data generated on these controls are provided in Table 2 showing 9_% variation for the positive control, __ for the peptide control and 57% for the negative control. 3. STABILITY STUDIES A number of stability studies were carried out for the purpose of this validation: HOMOGENATE STABILITY In this case a sample was ho ogemsed and divided into aliquots. Over a seven day period, the same homogenate was tested on four occasions using aliquots stored at -20°C. 2-8°C, and on two occasions using aliquots stored at room temperature and 37 υ C. The r esults, outlined in Table 3, show that the light signal is stable, (1 iowmg or inter-assay variation, ver this period with storage ndit ons of -20 C. with some deterioration at 2-8 C, room temperature and 37 C. (b) STABILITY OF HOMOGENISING BUFFER (HB) This study was set up to determine the expiry date of homogenising buffer for production purposes. A similar protocol to that outlined in (a) above was followed with the results provided in Table 4. Again the results show that the HB is stable for use. [c) STABILITY OF PRIMARY ANTIBODY - WORKING STRENGTH Undiluted antibody can be stored frozen for an indefinite length f time. However antibody diluted to working strength using PBS/Tween 20 (0.05%) is not as stable as concentrated antibody and a stability study was therefore carried out. Antibody dilutions of 1 : IK were made on 9 occasions over a 72 day period. On the final day of the study, each of the 9 preparations was applied to an antigen coated plate and an ELISA carried out. The results are presented in Table 5 and from these data it can be seen that the working strength antibody is stable for at least a 70 day period. ( ά) STABILITY OF SAMPLE IN HOMOGENISING BUFFER BEFORE HOMOGENISATION This stability test was carried out to ensure that the assav would not be affected if some factor resulted in a delay in homogenising the sample after the HB had been added. Homogenising buffer was added to a sample in the ratio of lg of brain to 15ml of buffer and the mixture left at room temperature overnight (15 hours). The sample was homogenised after this time and an immunoassay carried out. The r esults are shown in Table 6 (- 2 samples tested one without and one with a delay). The treatment made no difference to the eventual -esuU. w 15 5 0 5 Table 1 : Inter-assay variation data, generated on a single positive and negative control sample, in 10 assays. Assay Blank 'Neg' os' Peptide Number Control Control Control 1 2 4 30834 1 10524 day I 2 2 1 33789 105242 day I 3 2 12 35 19 104293 day I 4 1 2 32533 101227 dav 2 5 π 1 35424 1 14084 dav 2 6 15 1749 12 122 day 7 28 50 22732 1461 10 day 3 8 7 1 29143 1 14355 day 4 9 18 22 28565 1 1 1084 day 4 10 1 12 36213 100920 day 4 * T he value stated at each data point is the mean value of replicates of each control in the assays The overall mean stated below is calculated using every individual replicate value The values are quoted in chemiluininescence liulit units - LU Blank 'Neg " Control 'Pos ' Conttol Peptide Control Mean ~ 1 1 Mean _ 16 Mean - 3 1927 Mean - 1 1 169 SD - 10 SD - 1 5 SD - 5954 SD ■ = 1533 CV - 91% CV - 93% CV - 19% CV - 14% π - 46 n - 51 n - 51 n - 42 Table 2 : Infra-assay variation data, generated on a single positive and negative control sample, 23 replicates of each on a single plate. Replicate 1 FHa k 'Neg' 'Pos' Peptide Number Control Control Control 1 34 69 19857 96632 2 49 34 17738 95999 3 22 39 18354 1 12017 4 29 87 19645 121987 38 18975 1 19077 6 51 149 19828 1 18386 7 34 32 16466 103699 8 38 40 18259 106592 9 24 1 19840 1 19148 10 32 155 22813 101386 1 1 26 20 23004 88538 12 17 84 22153 99612 1 57 46 21880 99803 14 32 28 21722 92699 15 25 30 21069 1 17642 1 57 137 18524 82359 17 18 4 1 19644 88442 18 45 46 22478 9773 1 19 15 162 21596 92286 20 20 34 22438 1 15472 21 13 21 21661 1 18239 22 33 21 201 13 97596 23 19 13 20007 93713 * 1 he values aie quoted in ι chemiliiminescence light units - I .U Blank 'Neg ' Control 'Pos ' O nntrol Peptide Control Mean _ 2 Mean - 72 Mean = 20351 Mean =- 104742 SD - 13 SD - 4 1 SD - 1753 SD = 1 1601 CV - 4 1% CV - 57% CV = 9.0% CV = 1 1% n - 23 u ~ 23 n = 23 n = 23 Table 3 : Homogenate Stability Study - mean of 3 replicates at each temperature POSITIVE CONTROL Day -20°C 2-8°C RT 37°C 0 1550 2 1073 449 664 205 3 1162 413 - - 5 2025 887 - - 7 1661 1198 709 472 30 90 180 NEGATIVE CONTROL Day -20°C 2-8°C RT 37°C 0 39 2 10 15 6 6 3 9 12 - 5 17 37 - 7 20 31 10 I I 30 90 180 I he value at each data point is represented bv 3 replicates. Table 4 : Homogenising Buffer Stability Study - mean of 3 replicates at each temperature POSITIVE CONTROL Day -20°C 2-8°C RT 37°C 0 24719 2 53526 61248 42873 47088 3 3 1593 24762 7 32420 34457 36337 35010 30 60 180 NEGATIVE CONTROL Day -20°C 2-8°C RT 37° 0 7 2 4 6 3 4 3 - 9 9 - 7 14 16 20 14 30 60 180 I he value at each data point is represented bv 3 replicates. Table 5 : Primary Antibody Stability Study )ay 1° Antibody Mean Light SD - 8 % Signal Replicates CV 1 19849 557 2.8 3 17677 77 0.4 4 21796 340 1.6 9 18283 2 18 1 .2 23 16805 282 1 7 25 21285 377 1 8 30 21059 27 2.0 2 1 339 1 9 72 1 7774 5 1 1 2.9 Table 6 : Study of sample stability in ///? for a 15 hour period before homogenising Sample I.I). Hours before homogenisation Mean Result (LU) 79 73233 OS 72578 80 o 18 NEG 15 38 * • I he mean values stated represent 4 replicates at each data point.

Claims: CLAIMS 1. Λ method for detecting the putative agent for TSE in animals comDrising taking a body tissue sample from an animal, reacting the sample in a immunological assay with a labelled antibody which is ccaappaabbllee ooff rreeaaccttiinngg wwiitthh PPrrPPsc and determining the amount of labelled antibody bound to the sample. 2. A method as claimed in claim 1 wherein the antibody used in the assay is raised against a synthetic peptide sequence having the general foπnuI : X-(R,-Lys-His-R ? )-Ala-Gly-Ala-Ala-Aιa-R ~ -Gly-Ala-Va " i-VaI-Gly-G 1 v-Leu-Glv-Gl v-Tvr-Met-Leu-Glv-Ser-Ala-Met-Ser-(Arq-Pro-R,-R,.) -Y wherein R 1 is an amino acid residue selected from Met, Leu and Phe; R ? is either Met or Val; R, is Ala or is absent; R. and Rr are independently an amino acid residue selected from Leu, He and Met; one or more residues within brackets maybe present or absent with the provisio that if they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently be absent or independently be one or more additional amino acid residues. 3. A method as claimed in any preceding claim wherein the antibodies are prion specific antibodies raised against one or more of the following sequences: MVKSHIGSWILVLrVVAMWSDVGLCKKRPKPGGGHNTGGSRYPGO-44 GSPGGNRYPPQGGGGWGOPHGGGMGflPHGGGWGOPHGGGOGOP-87 GGGGWGOGGSHSOWNKPSKPPKTNMKHVAGAAAGAVVGGLGGY-1 1 MLGSAMSSPLIHFGNDYEDRYTRENMYRYPNQVYYRPVDRYSNQNN-177 4. A method as claimed in claim 3 wherein the antibodies are antibodies raised aαainst the underlined seuuences shown in claim 3. 5. A method as claimed in any preceding claim wherein the immunological assay may be a competitive assay in which a solid support, suitably a microtitre plate, is pre-coated with a carrier protein-peptide conjugate, the animal tissue sample and an anti-peptide antibody are added to the solid support, allowed to react and the support washed, a labelled anti-(antι-peptide antibody) antibody is added, allowed to react, washed, a signal reagent added and the signal ead. 6. The method as claimed in any preceding claim wherein the animals are selected from cattle, sheep and pigs and the tissue sample is taken from a carcass of such animals. 7. A method as claimed in any preceding claim wherein a sample of CNS tissue, suitably a cross-section of spinal cord, is used for testing. 8. A test kit for the detection of TSE in animals comprising an anti-peptide antibody raised against a synthetic peptide sequence having the general formula: X-(R 1 -Lys-His-R 2 )-Ala-Gly-Ala-Ala-Ala-R 3 -Gly-Ala-Val-Val-Gly-G ly-Leu-Gly-Gly-Tyr-Met-Leu-Gly-Ser-Ala-Met-Ser-(Arg-Pro-R 4 -R 5 )-Y wherein R, is an amino acid residue selected from Met, Leu and Phe; is either Met or Val; R., is Ala cr is absent; R 4 and Rr are independently an amino acid residue selected from Leu, He and Met; one or more residues within brackets maybe present or absent with the provisio that if they are present they are attached to the rest of the peptide in sequence; and X and Y may each independently be absent or independently be one or more additional amino acid residues.

Inventors: O'CONNOR MICHAEL, O'CONNOR, MICHAEL
Applicants: CONNOR MICHAEL O, ENFER TECH LTD, ENFER TECHNOLOGY LIMITED, O'CONNOR, MICHAEL
Application year: 1998
Main classification: G01N33
IPC codes: C07K14, C07K16